前沿速览008期| CAR-T治B淋 前沿览新知
01
Lisocabtagene Maraleucel治疗复发/难治性套细胞淋巴瘤：来自TRANSCEND NHL 001的MCL队列初步分析，一项I期多中心无缝设计研究
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study
第一作者：Wang M
J Clin Oncol (IF=45.3). 2023 Dec 10:101200JCO2302214.
全文网址：https://ascopubs.org/doi/10.1200/JCO.23.02214?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
02
一种新型抗CD19 CAR-T细胞产品（靶向CD19膜近端域，具有快速的开关速率）治疗非霍奇金淋巴瘤的安全性和有效性：首次人体研究
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
第一作者：Zhang Y
Mol Cancer (IF=37.3). 2023 Dec 9;22(1):200.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10709913/
03
利用病毒模拟熔融纳米颗粒在体内生产 CAR-T 细胞
In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles
第一作者：Zhao G
Sci Bull (Beijing) (IF=18.9). 2023 Dec 1:S2095-9273(23)00837-X.
全文网址：https://www.sciencedirect.com/science/article/pii/S209592732300837X?via%3Dihub
04
T细胞的内在缺陷影响CAR-T疗法在弥漫性大B细胞淋巴瘤患者中的疗效
The intrinsic defects of T cells impact the efficacy of CAR-T therapy in patients with diffuse large B-cell lymphoma
第一作者：Zhao J
Blood Cancer J (IF=12.8). 2023 Dec 14;13(1):186.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10721638/
05
血液恶性肿瘤治疗中自体 CAR-T 细胞制造和/或疗效失败的早期预测因素
Early predictive factors of failure in autologous CAR T-cells manufacturing and/or efficacy in hematologic malignancies
第一作者：Baguet C
Blood Adv (IF=7.5). 2023 Dec 5:bloodadvances.2023011992.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023011992/506509/Early-predictive-factors-of-failure-in-autologous
06
Axi-cel治疗大B细胞淋巴瘤前的桥接治疗：来自美国淋巴瘤CAR-T联盟的结果
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US lymphoma CAR-T consortium
第一作者：Jain MD
Blood Adv (IF=7.5). 2023 Nov 16:bloodadvances.2023011489.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023011489/498755/Bridging-therapy-with-axicabtagene-ciloleucel-for
07
CAR-T细胞在当前适应症之外的潜在应用
Broadening the horizon: potential applications of CAR-T cells beyond current indications
第一作者：Karsten H
Front Immunol (IF=7.3). 2023 Nov 27;14:1285406.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10711079/
08
无论是否累及中枢神经系统，CAR-T细胞疗法在DLBCL患者中均显示出相似的疗效和毒性
CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement
第一作者：Shumilov E
Hemasphere (IF=6.6). 2023 Nov 30;7(12):e984.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691788/
09
FDG PET/CT在接受CAR-T细胞治疗的淋巴瘤患者中的作用：当前概念
Role of FDG PET/CT in Patients With Lymphoma Treated With CAR T-Cell Therapy: Current Concepts
第一作者：Murad V
AJR Am J Roentgenol (IF=5.0). 2023 Dec 6.
全文网址：https://www.ajronline.org/doi/10.2214/AJR.23.30301
10
CAR-T细胞治疗后循环肿瘤DNA可用于预警弥漫大B细胞淋巴瘤的超进展：病例报告和文献综述
Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review
第一作者：He J
Front Oncol (IF=4.7). 2023 Nov 28;13:1283194.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10713792/
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2023.12-26 valid until 2025.12
供稿与审核：临床开发与医学部